5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma
作者:Dylan J. Kahl、Kim M. Hutchings、Erika Mathes Lisabeth、Andrew J. Haak、Jeffrey R. Leipprandt、Thomas Dexheimer、Dinesh Khanna、Pei-Suen Tsou、Phillip L. Campbell、David A. Fox、Bo Wen、Duxin Sun、Marc Bailie、Richard R. Neubig、Scott D. Larsen
DOI:10.1021/acs.jmedchem.8b01772
日期:2019.5.9
Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM). We were able to rapidly improve the cellular potency by 5 orders of magnitude
通过使用血清反应元件荧光素酶启动子的表型高通量筛选,我们确定了Rho /心肌素相关转录因子(MRTF)/血清的新型5-芳基-1,3,4-恶二唑-2-基硫代丙酸铅抑制剂响应因子(SRF)介导的基因转录具有良好的效能(IC50 = 180 nM)。在清晰定义和协同作用的SAR的指导下,我们能够将细胞效能快速提高5个数量级。SAR的强大效能和深度,以及该系列相对较低的分子量,表明但不证明与未知分子靶标的结合可能是通过共价机制发生的。然而,该系列在高达100μM的浓度下没有可观察到的细胞毒性。